A DNA Damage Response Related Signature to Predict Prognosis in Patients with Acute Myeloid Leukemia

References

• Vago L, Gojo I. Immune escape and immunotherapy of acute myeloid leukemia. J Clin Invest. 2020;130(4):1552–1564. doi:10.1172/JCI129204.
   PubMed Web of Science ®Google Scholar
• Liu H. Emerging agents and regimens for AML. J Hematol Oncol. 2021;14(1):49. doi:10.1186/s13045-021-01062-w.
   PubMed Web of Science ®Google Scholar
• Rowe JM. Perspectives on current survival and new developments in AML. Best Pract Res Clin Haematol. 2021;34(1):101248. doi:10.1016/j.beha.2021.101248.
   PubMed Web of Science ®Google Scholar
• Tettamanti S, Pievani A, Biondi A, Dotti G, Serafini M. Catch me if you can: how AML and its niche escape immunotherapy. Leukemia. 2022;36(1):13–22. doi:10.1038/s41375-021-01350-x.
   PubMed Web of Science ®Google Scholar
• Winer ES, Stone RM. Novel therapy in acute myeloid leukemia (AML): moving toward targeted approaches. Ther Adv Hematol. 2019;10:2040620719860645. doi:10.1177/2040620719860645.
   Web of Science ®Google Scholar
• Gao C, Zhuang J, Zhou C, Liu L, Liu C, Li H, et al. Developing DNA methylation-based prognostic biomarkers of acute myeloid leukemia. J Cell Biochem. 2018;119(12):10041–10050.
   PubMed Web of Science ®Google Scholar
• Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345–1377.
   PubMed Web of Science ®Google Scholar
• Moarii M, Papaemmanuil E. Classification and risk assessment in AML: integrating cytogenetics and molecular profiling. Hematol Am Soc Hematol Educ Program. 2017;2017(1):37–44. doi:10.1182/asheducation-2017.1.37.
   PubMedGoogle Scholar
• Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson AG, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. New Eng J Med. 2013;368(22):2059–2074.
   PubMed Web of Science ®Google Scholar
• Chuang MK, Chiu YC, Chou WC, Hou HA, Chuang EY, Tien HF. A 3-microRNA scoring system for prognostication in de novo acute myeloid leukemia patients. Leukemia. 2015;29(5):1051–1059. doi:10.1038/leu.2014.333.
   PubMed Web of Science ®Google Scholar
• Zhu R, Lin W, Zhao W, Fan F, Tang L, Hu Y. A 4-microRNA signature for survival prognosis in pediatric and adolescent acute myeloid leukemia. J Cell Biochem. 2019;120(3):3958–3968.
   PubMed Web of Science ®Google Scholar
• Elsayed AH, Rafiee R, Cao X, Raimondi S, Downing JR, Ribeiro R, et al. A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia. Leukemia. 2020;34(3):735–745. doi:10.1038/s41375-019-0604-8.
   PubMed Web of Science ®Google Scholar
• Li R, Ding Z, Jin P, Wu S, Jiang G, Xiang R, et al. Development and validation of a novel prognostic model for acute myeloid leukemia based on immune-related genes. Front Immunol. 2021;12:639634.
   PubMed Web of Science ®Google Scholar
• Wagner S, Vadakekolathu J, Tasian SK, Altmann H, Bornh?User M, Pockley AG, Ball GR. Rutella S: A parsimonious 3-gene signature predicts clinical outcomes in an acute myeloid leukemia multicohort study. Blood Adv . 2019;3(8):1330–1346.
   PubMed Web of Science ®Google Scholar
• Estey EH. Therapeutic options for acute myelogenous leukemia. Cancer. 2001;92(5):1059–1073.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Qing B, Xu C, Zhao J, Liao Y, Cui P, et al. DNA damage response gene-based subtypes associated with clinical outcomes in early-stage lung adenocarcinoma. Front Mol Biosci. 2022;9:901829.
   PubMed Web of Science ®Google Scholar
• Zhuang W, Ben X, Zhou Z, Ding Y, Tang Y, Huang S, et al. Identification of a ten-gene signature of DNA damage response pathways with prognostic value in esophageal squamous cell carcinoma. J Oncol. 2021;2021:3726058.
   PubMed Web of Science ®Google Scholar
• Zhan J, Wu S, Zhao X, Jing J. A novel DNA damage repair-related gene signature for predicting glioma prognosis. Int J Gen Med. 2021;14:10083–10101.
   PubMed Web of Science ®Google Scholar
• Ying J, Yang L, Yin JC, Xia G, Xing M, Chen X, et al. Additive effects of variants of unknown significance in replication repair-associated DNA polymerase genes on mutational burden and prognosis across diverse cancers. J Immunother Cancer. 2021;9(9):e002336.
   PubMed Web of Science ®Google Scholar
• Popp HD, Naumann N, Brendel S, Henzler T, Weiss C, Hofmann WK, Fabarius A. Increase of DNA damage and alteration of the DNA damage response in myelodysplastic syndromes and acute myeloid leukemias. Leuk Res. 2017;57:112–118. doi:10.1016/j.leukres.2017.03.011.
   PubMed Web of Science ®Google Scholar
• Park S, Kim YJ, Huh HJ, Chung HS, Lee M, Park YM, et al. Comprehensive DNA repair gene expression analysis and its prognostic significance in acute myeloid leukemia. Hematology. 2021;26(1):904–913.
   PubMed Web of Science ®Google Scholar
• Gbadamosi MO, Shastri VM, Elsayed AH, Ries R, Olabige O, Nguyen NHK, et al. A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials. Leukemia. 2022;36(8):2022–2031. doi:10.1038/s41375-022-01622-0.
   PubMed Web of Science ®Google Scholar
• Wang YH, Lin CC, Hsu CL, Hung SY, Yao CY, Lee SH, et al. Distinct clinical and biological characteristics of acute myeloid leukemia with higher expression of long noncoding RNA KIAA0125. Ann Hematol. 2021;100(2):487–498. doi:10.1007/s00277-020-04358-y.
   PubMed Web of Science ®Google Scholar
• Knijnenburg TA, Wang L, Zimmermann MT, Chambwe N, Gao GF, Cherniack AD, et al. Genomic and molecular landscape of DNA damage repair deficiency across the cancer genome atlas. Cell Rep. 2018;23(1):239–254.e6. e236.
   PubMed Web of Science ®Google Scholar
• Yang Y, Wu G, Li Q, Zheng Y, Liu M, Zhou L, et al. Angiogenesis-related immune signatures correlate with prognosis, tumor microenvironment, and therapeutic sensitivity in hepatocellular carcinoma. Front Mol Biosci. 2021;8:690206.
   PubMed Web of Science ®Google Scholar
• Gamis AS, Alonzo TA, Meshinchi S, Sung L, Gerbing RB, Raimondi SC, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. J Clin Oncol. 2014;32(27):3021–3032.
   PubMed Web of Science ®Google Scholar
• Mouw KW, Goldberg MS, Konstantinopoulos PA, D'Andrea AD. DNA damage and repair biomarkers of immunotherapy response. Cancer Discov. 2017;7(7):675–693. doi:10.1158/2159-8290.CD-17-0226.
   PubMed Web of Science ®Google Scholar
• Ishikawa Y, Nakayama K, Morimoto M, Mizutani A, Nakayama A, Toyoshima K, et al. Synergistic anti-AML effects of the LSD1 inhibitor T-3775440 and the NEDD8-activating enzyme inhibitor pevonedistat via transdifferentiation and DNA rereplication. Oncogenesis. 2017;6(9):e377.
   PubMedGoogle Scholar
• Opydo-Chanek M, Cichoń I, Rak A, Kołaczkowska E, Mazur L. The pan-Bcl-2 inhibitor obatoclax promotes differentiation and apoptosis of acute myeloid leukemia cells. Invest New Drugs. 2020;38(6):1664–1676. doi:10.1007/s10637-020-00931-4.
   PubMed Web of Science ®Google Scholar
• Pollard JA, Guest E, Alonzo TA, Gerbing RB, Loken MR, Brodersen LE, Kolb EA, et al. Gemtuzumab ozogamicin improves event-free survival and reduces relapse in pediatric KMT2A-rearranged AML: results from the Phase III Children’s Oncology Group Trial AAML0531. J Clin Oncol. 2021;39(28):3149–3160.
   PubMed Web of Science ®Google Scholar
• Nair R, Salinas-Illarena A, Baldauf HM. New strategies to treat AML: novel insights into AML survival pathways and combination therapies. Leukemia. 2021;35(2):299–311. doi:10.1038/s41375-020-01069-1.
   PubMed Web of Science ®Google Scholar
• Montalban-Bravo G, DiNardo CD. The role of IDH mutations in acute myeloid leukemia. Future Oncol. 2018;14(10):979–993. doi:10.2217/fon-2017-0523.
   PubMed Web of Science ®Google Scholar
• Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Kronke J, Bullinger L, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol. 2010;28(22):3636–3643.
   PubMed Web of Science ®Google Scholar
• Pashaiefar H, Yaghmaie M, Tavakkoly-Bazzaz J, Ghaffari SH, Alimoghaddam K, Momeny M, et al. PARP-1 overexpression as an independent prognostic factor in adult non-M3 acute myeloid leukemia. Genet Test Mol Biomarkers. 2018;22(6):343–349. doi:10.1089/gtmb.2018.0085.
   PubMed Web of Science ®Google Scholar
• Wang L, Cai W, Zhang W, Chen X, Dong W, Tang D, et al. Inhibition of poly(ADP-ribose) polymerase 1 protects against acute myeloid leukemia by suppressing the myeloproliferative leukemia virus oncogene. Oncotarget. 2015;6(29):27490–27504.
   PubMedGoogle Scholar
• Li X, Li C, Jin J, Wang J, Huang J, Ma Z, et al. High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects. EBioMedicine. 2018;38:47–56.
   PubMed Web of Science ®Google Scholar
• Feng J-H, Guo X-P, Chen Y-Y, Wang Z-J, Cheng Y-P, Tang Y-M. Prognostic significance of IDH1 mutations in acute myeloid leukemia: a meta-analysis. Am J Blood Res. 2012;2(4):254–264.
   PubMedGoogle Scholar
• Vadakekolathu J, Minden MD, Hood T, Church SE, Reeder S, Altmann H, et al. Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia. Sci Transl Med. 2020;12(546):eaaz0463.
   PubMed Web of Science ®Google Scholar
• Sanchez-Correa B, Campos C, Pera A, Bergua JM, Arcos MJ, Bañas H, et al. Natural killer cell immunosenescence in acute myeloid leukaemia patients: new targets for immunotherapeutic strategies? Cancer Immunol Immunother. 2016;65(4):453–463.
   PubMed Web of Science ®Google Scholar
• Aggarwal N, Swerdlow SH, TenEyck SP, Boyiadzis M, Felgar RE. Natural killer cell (NK) subsets and NK-like T-cell populations in acute myeloid leukemias and myelodysplastic syndromes. Cytometry B Clin Cytom. 2016;90(4):349–357.
   PubMed Web of Science ®Google Scholar
• Feng J, Zhang W, Wu J, Gao S, Ye H, Sun L, et al. Effect of initial absolute monocyte count on survival outcome of patients with de novo non-M3 acute myeloid leukemia. Leuk Lymphoma. 2016;57(11):2548–2554.
   PubMed Web of Science ®Google Scholar
• Al-Matary YS, Botezatu L, Opalka B, Hönes JM, Lams RF, Thivakaran A, et al. Acute myeloid leukemia cells polarize macrophages towards a leukemia supporting state in a growth factor independence 1 dependent manner. Haematologica. 2016;101(10):1216–1227.
   PubMed Web of Science ®Google Scholar
• Xiao W, Chan A, Waarts MR, Mishra T, Liu Y, Cai SF, et al. Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia. Blood. 2021;137(10):1377–1391.
   PubMed Web of Science ®Google Scholar
• Wei Y, Cao Y, Sun R, Cheng L, Xiong X, Jin X, et al. Targeting Bcl-2 proteins in acute myeloid leukemia. Front Oncol. 2020;10:584974.
   PubMedGoogle Scholar
• Röllig C, Serve H, Noppeney R, Hanoun M, Krug U, Baldus CD, et al. Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial. Leukemia. 2021;35(9):2517–2525. doi:10.1038/s41375-021-01148-x.
   PubMed Web of Science ®Google Scholar
• Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature. 2009;458(7239):732–736.
   PubMed Web of Science ®Google Scholar
• Sekeres MA, Watts J, Radinoff A, Sangerman MA, Cerrano M, Lopez PF, et al. Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML. Leukemia. 2021;35(7):2119–2124.
   PubMed Web of Science ®Google Scholar